IC Targets
About[edit]
IC Targets AS (Norwegian Contrasts) is a Norwegian life science company developing novel MRI contrast agents based on manganese chemistry. Founded in 2002, making it one of the oldest companies in the NHT cluster.
Technology[edit]
The company's core innovation is manganese-based MRI contrast agents. Conventional MRI contrast agents are based on gadolinium, which has raised safety concerns due to deposition in brain tissues and kidneys. Manganese is a naturally occurring mineral (essential trace element) that can serve as an alternative MRI contrast agent, potentially offering improved safety profiles.
Market Need[edit]
Gadolinium-based contrast agents are used in approximately 30-50% of MRI examinations globally. Growing concerns about gadolinium retention in the brain and other tissues have created interest in alternative contrast technologies. A manganese-based agent that maintains diagnostic efficacy while reducing safety concerns would address a significant market need.